Free Trial

ResMed (RMD) Competitors

ResMed logo
$258.09 +2.11 (+0.83%)
Closing price 07/10/2025 03:59 PM Eastern
Extended Trading
$254.90 -3.19 (-1.24%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RMD vs. MEDP, EHC, HIMS, SYK, MDT, BDX, EW, IDXX, DXCM, and STE

Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), and STERIS (STE). These companies are all part of the "medical" sector.

ResMed vs. Its Competitors

ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

ResMed has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

ResMed has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$4.69B8.08$1.02B$8.9128.97
Medpace$2.11B4.47$404.39M$13.1025.06

55.0% of ResMed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, ResMed had 1 more articles in the media than Medpace. MarketBeat recorded 19 mentions for ResMed and 18 mentions for Medpace. ResMed's average media sentiment score of 1.27 beat Medpace's score of 0.80 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
16 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
7 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ResMed presently has a consensus target price of $259.33, suggesting a potential upside of 0.48%. Medpace has a consensus target price of $344.82, suggesting a potential upside of 5.05%. Given Medpace's higher possible upside, analysts plainly believe Medpace is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.64
Medpace
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

ResMed has a net margin of 26.15% compared to Medpace's net margin of 19.31%. Medpace's return on equity of 54.36% beat ResMed's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed26.15% 25.67% 18.59%
Medpace 19.31%54.36%20.81%

Summary

ResMed beats Medpace on 10 of the 17 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RMD vs. The Competition

MetricResMedMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$37.53B$10.57B$5.55B$20.59B
Dividend Yield0.83%2.08%5.25%3.73%
P/E Ratio28.9716.5627.2028.00
Price / Sales8.0829.83413.3354.26
Price / Cash27.7422.8437.5022.41
Price / Book7.803.758.084.61
Net Income$1.02B$235.43M$3.16B$982.91M
7 Day Performance0.44%3.78%4.68%3.27%
1 Month Performance2.75%4.28%4.49%4.46%
1 Year Performance29.19%-12.03%30.99%12.40%

ResMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RMD
ResMed
4.6776 of 5 stars
$258.09
+0.8%
$259.33
+0.5%
+34.2%$37.53B$4.69B28.979,980Positive News
Insider Trade
MEDP
Medpace
4.5401 of 5 stars
$318.90
-0.8%
$344.82
+8.1%
-21.7%$9.17B$2.11B24.345,900Trending News
Analyst Revision
EHC
Encompass Health
4.9685 of 5 stars
$119.22
+0.2%
$127.00
+6.5%
+38.7%$12.02B$5.37B24.6340,000Positive News
HIMS
Hims & Hers Health
2.2548 of 5 stars
$48.34
+0.8%
$39.58
-18.1%
+148.6%$10.82B$1.78B70.061,637Trending News
Insider Trade
SYK
Stryker
4.6427 of 5 stars
$392.26
-0.8%
$427.30
+8.9%
+17.0%$149.72B$22.60B53.0153,000Positive News
Analyst Forecast
MDT
Medtronic
4.6299 of 5 stars
$87.73
-0.7%
$97.87
+11.6%
+16.0%$112.52B$33.54B24.2395,000Trending News
Analyst Forecast
BDX
Becton, Dickinson and Company
4.8594 of 5 stars
$172.92
-1.8%
$219.22
+26.8%
-20.8%$49.56B$20.18B33.0074,000Positive News
EW
Edwards Lifesciences
4.518 of 5 stars
$76.64
-0.2%
$80.20
+4.6%
-16.0%$44.96B$5.44B10.9515,800Positive News
Analyst Forecast
IDXX
IDEXX Laboratories
3.9229 of 5 stars
$545.56
-0.3%
$558.11
+2.3%
+11.9%$43.87B$3.90B50.4211,000Positive News
DXCM
DexCom
4.8791 of 5 stars
$82.94
+0.0%
$98.50
+18.8%
-22.9%$32.52B$4.03B61.9010,300Positive News
STE
STERIS
4.909 of 5 stars
$233.09
-1.9%
$263.83
+13.2%
+7.0%$22.93B$5.46B37.6017,787Positive News

Related Companies and Tools


This page (NYSE:RMD) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners